{
    "xml": "<topic id=\"PHP1020\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/sotalol-hydrochloride\" basename=\"sotalol-hydrochloride\" title=\"SOTALOL HYDROCHLORIDE\">\n<title>SOTALOL HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_455\" namespace=\"/interactions/list-of-drug-interactions/beta-blockers/sotalol\">Sotalol</xref>\n</p>\n<data name=\"vtmid\">96301002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_613648210\" title=\"Beta-adrenoceptor blockers\">Beta-adrenoceptor blockers</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34515\" title=\"BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)\" namespace=\"/drug-classes/beta-adrenoceptor-blockers-systemic\">BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP53308\" outputclass=\"indicationsAndDose\" rev=\"1.30\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic non-sustained ventricular tachyarrhythmias</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of paroxysmal atrial tachycardia or fibrillation, paroxysmal AV re-entrant tachycardias (both nodal and involving accessory pathways), and paroxysmal supraventricular tachycardia after cardiac surgery</p>\n<p outputclass=\"therapeuticIndication\">Maintenance of sinus rhythm following cardioversion of atrial fibrillation or flutter</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 80&#8239;mg daily in 1&#8211;2 divided doses, then increased to 160&#8211;320&#8239;mg daily in 2 divided doses, dose to be increased gradually at intervals of 2&#8211;3 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Life-threatening arrhythmias including ventricular tachyarrhythmias (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 80&#8239;mg daily in 1&#8211;2 divided doses, then increased to 480&#8211;640&#8239;mg daily in 2 divided doses, dose to be increased gradually at intervals of 2&#8211;3 days.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53418\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Sotalol may prolong the QT interval, and it occasionally causes life threatening ventricular arrhythmias (<b>important</b>: particular care is required to avoid hypokalaemia in patients taking sotalol&#8212;electrolyte disturbances, particularly hypokalaemia and hypomagnesaemia should be corrected before sotalol started and during use).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53423\" outputclass=\"contraindications\" rev=\"1.12\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Long QT syndrome (congenital or acquired)</ph>; <ph outputclass=\"contraindication\">torsade de pointes</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53449\" outputclass=\"cautions\" rev=\"1.18\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Diarrhoea (severe or prolonged)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53295\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Extreme caution or avoid concomitant use of drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53256\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arrhythmogenic (pro-arrhythmic) effect (torsade de pointes&#8212;increased risk in females)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53459\" outputclass=\"breastFeeding\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Water soluble beta-blockers such as sotalol are present in breast milk in greater amounts than other beta blockers.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53269\" outputclass=\"renalImpairment\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Use half normal dose if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; use one-quarter normal dose if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53220\" outputclass=\"monitoringRequirements\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Measurement of corrected QT interval, and monitoring of ECG and electrolytes required; correct hypokalaemia, hypomagnesaemia, or other electrolyte disturbances.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1020-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/sotalol-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75875\" title=\"Tablet\" namespace=\"/drugs/sotalol-hydrochloride/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78218\" namespace=\"/treatment-summaries/beta-adrenoceptor-blocking-drugs\" title=\"Beta-adrenoceptor blocking drugs\" count=\"2\" rel=\"backlink\">Beta-adrenoceptor blocking drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78291\" namespace=\"/treatment-summaries/arrhythmias\" title=\"Arrhythmias\" count=\"7\" rel=\"backlink\">Arrhythmias</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_455\" namespace=\"/interactions/list-of-drug-interactions/beta-blockers/sotalol\" title=\"Sotalol\" count=\"1\" rel=\"link\">Sotalol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34515\" namespace=\"/drug-classes/beta-adrenoceptor-blockers-systemic\" title=\"BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)\" count=\"1\" rel=\"link\">BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75875\" namespace=\"/drugs/sotalol-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP1020",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/sotalol-hydrochloride",
    "basename": "sotalol-hydrochloride",
    "title": "SOTALOL HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_455",
            "label": "Sotalol"
        }
    ],
    "vtmid": "96301002",
    "drugClassification": [
        "Beta-adrenoceptor blockers"
    ],
    "inheritsFromClass": [
        "BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Symptomatic non-sustained ventricular tachyarrhythmias",
                        "html": "Symptomatic non-sustained ventricular tachyarrhythmias"
                    },
                    {
                        "textContent": "Prophylaxis of paroxysmal atrial tachycardia or fibrillation, paroxysmal AV re-entrant tachycardias (both nodal and involving accessory pathways), and paroxysmal supraventricular tachycardia after cardiac surgery",
                        "html": "Prophylaxis of paroxysmal atrial tachycardia or fibrillation, paroxysmal AV re-entrant tachycardias (both nodal and involving accessory pathways), and paroxysmal supraventricular tachycardia after cardiac surgery"
                    },
                    {
                        "textContent": "Maintenance of sinus rhythm following cardioversion of atrial fibrillation or flutter",
                        "html": "Maintenance of sinus rhythm following cardioversion of atrial fibrillation or flutter"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 80 mg daily in 1&#8211;2 divided doses, then increased to 160&#8211;320 mg daily in 2 divided doses, dose to be increased gradually at intervals of 2&#8211;3 days.",
                        "html": "<p>Initially 80&#8239;mg daily in 1&#8211;2 divided doses, then increased to 160&#8211;320&#8239;mg daily in 2 divided doses, dose to be increased gradually at intervals of 2&#8211;3 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Life-threatening arrhythmias including ventricular tachyarrhythmias (under expert supervision)",
                        "html": "Life-threatening arrhythmias including ventricular tachyarrhythmias (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 80 mg daily in 1&#8211;2 divided doses, then increased to 480&#8211;640 mg daily in 2 divided doses, dose to be increased gradually at intervals of 2&#8211;3 days.",
                        "html": "<p>Initially 80&#8239;mg daily in 1&#8211;2 divided doses, then increased to 480&#8211;640&#8239;mg daily in 2 divided doses, dose to be increased gradually at intervals of 2&#8211;3 days.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "Sotalol may prolong the QT interval, and it occasionally causes life threatening ventricular arrhythmias (important: particular care is required to avoid hypokalaemia in patients taking sotalol&#8212;electrolyte disturbances, particularly hypokalaemia and hypomagnesaemia should be corrected before sotalol started and during use).",
                "html": "<p>Sotalol may prolong the QT interval, and it occasionally causes life threatening ventricular arrhythmias (<b>important</b>: particular care is required to avoid hypokalaemia in patients taking sotalol&#8212;electrolyte disturbances, particularly hypokalaemia and hypomagnesaemia should be corrected before sotalol started and during use).</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Long QT syndrome (congenital or acquired)",
                "html": "Long QT syndrome (congenital or acquired)"
            },
            {
                "type": "contraindications",
                "textContent": "torsade de pointes",
                "html": "torsade de pointes"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Diarrhoea (severe or prolonged)",
                "html": "Diarrhoea (severe or prolonged)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Extreme caution or avoid concomitant use of drugs that prolong QT interval.",
                "html": "<p>Extreme caution or avoid concomitant use of drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Arrhythmogenic (pro-arrhythmic) effect (torsade de pointes&#8212;increased risk in females)",
                        "html": "Arrhythmogenic (pro-arrhythmic) effect (torsade de pointes&#8212;increased risk in females)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Water soluble beta-blockers such as sotalol are present in breast milk in greater amounts than other beta blockers.",
                "html": "<p>Water soluble beta-blockers such as sotalol are present in breast milk in greater amounts than other beta blockers.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Use half normal dose if eGFR 30&#8211;60 mL/minute/1.73 m2; use one-quarter normal dose if eGFR 10&#8211;30 mL/minute/1.73 m2.",
                "html": "<p>Use half normal dose if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; use one-quarter normal dose if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if eGFR less than 10 mL/minute/1.73 m2.",
                "html": "<p>Avoid if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Measurement of corrected QT interval, and monitoring of ECG and electrolytes required; correct hypokalaemia, hypomagnesaemia, or other electrolyte disturbances.",
                "html": "<p>Measurement of corrected QT interval, and monitoring of ECG and electrolytes required; correct hypokalaemia, hypomagnesaemia, or other electrolyte disturbances.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75875",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78218",
                "label": "Beta-adrenoceptor blocking drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78291",
                "label": "Arrhythmias",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_455",
                "label": "Sotalol",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34515",
                "label": "BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75875",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}